William L. Greene, MD

Chief Executive Officer

Dr. Greene has served as Chief Executive Officer and a Director of Iconic Therapeutics since April 2014. He brings 20 years of experience as an operating executive, clinician, investor, and entrepreneur. Dr. Greene joined Iconic from MPM Capital LLC, where he served as Managing Director and a member of the firm’s Investment Committee leading investments (including in Iconic) and serving on Boards of Directors of emerging biopharmaceutical and medical device companies.

Previously, Dr. Greene was a Senior Clinical Scientist and Epidemiologist at Genentech, Inc., with responsibility for clinical strategy, trial design and execution, and regulatory interactions in several therapeutic areas at all stages of development. While at Genentech, Dr. Greene led the early clinical development of Lucentis®. Prior to Genentech, Dr. Greene was at Yale Medical School where he was a Resident in Internal Medicine and Diagnostic Radiology. He has been an Assistant Clinical Professor of Medicine at UCSF, active on the teaching staff of San Francisco General Hospital.

Dr. Greene received a B.A. degree from Wesleyan University and an M.D. degree from UCSF and is a member of the American College of Physicians. He has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). Dr. Greene currently serves on the Board of Sai Advantium Pharma and is a co-founder of and Senior Advisor to Pear Therapeutics. He is a long-standing advisor to the Bill and Melinda Gates Foundation, and is Chairman of the Investment Committee and on the Board of its Global Health Investment Fund.

Gabriela Burian, MD, MPH

Chief Medical Officer

Dr. Burian brings to Iconic more than 15 years of clinical research and development experience focused on retinal disease, with extensive practice in designing, planning, and executing global clinical programs. Dr. Burian joined Novartis Pharma in 2005 as Clinical Research Scientist, where she later held various leadership and management positions including Global Program Medical Director. Dr. Burian was also responsible for clinical development strategies across multiple retinal indications, including age-related macular degeneration, diabetic macular edema (DME), retinal vein occlusion (RVO) and pathologic myopia (PM) and successfully led the global (ex-US) regulatory interactions and approvals of Lucentis® for DME, RVO and PM in more than 100 countries.

Most recently, Dr. Burian served as the Ophthalmology Early Program Leader at F. Hoffmann-La Roche, where she was responsible for establishing the translational medicine group and leading early clinical development strategy. Dr. Burian received her M.D. degree from Victor Babes University of Medicine and Pharmacy in Romania, and her Master’s in Public Health in Epidemiology from Rollins School of Public Health at Emory University. After completing her graduate work, Dr. Burian served at the Emory University’s Ophthalmology Department as the Clinical Research Manager and was a member of the faculty.